Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 59Neoplasms 6Neoplasm Metastasis 5Melanoma 5Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 4Ovarian Neoplasms 3Neoplasms by Site 3Hereditary Sensory and Autonomic Neuropathies 3Endometrial Neoplasms 3Breast Diseases 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Neuroblastoma 2Multiple Endocrine Neoplasia Type 1 2Lymphoma 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Teratoma 1Stomach Neoplasms 1Solid Tumors Harboring a BRAF V600 Mutation 1Solid Tumors 1Rhabdomyosarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteitis Deformans 1Neoplasms, Germ Cell and Embryonal 1

Interventions

Fluorouracil 12pembrolizumab 9Oxaliplatin 9Nivolumab 9Leucovorin 8Capecitabine 7Cisplatin 6Trastuzumab 4Paclitaxel 3Drug Therapy 3Docetaxel 3zimberelimab 2zanidatamab 2tucatinib 2spartalizumab 2durvalumab 2Radiotherapy 2Levoleucovorin 2Irinotecan 2Gemcitabine 2Carboplatin 2130-nm albumin-bound paclitaxel 2zolbetuximab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1toripalimab 1tislelizumab 1tezacitabine 1ribociclib 1quemliclustat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma Of Esophagus × ribociclib × Clear all
NCT05252416 2025-11-28

(VELA) Study of BLU-222 in Advanced Solid Tumors

Blueprint Medicines Corporation

Phase 1 Terminated
50 enrolled
GastrointestinalGynecologicSarcoma

Adenocarcinoma Of Esophagus, Carcinosarcoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡